The Evolving World of Oral SERDs: A Deep Dive into Patient Selection, Sequencing Strategies, and Emerging Data - Episode 6
Combination Strategies in HR+/HER2– mBC: Insights From the ELEVATE Trial
A panelist discusses how combination studies like ELEVATE are exploring elacestrant with other targeted therapies, showing promising results with ribociclib and everolimus combinations that are well-tolerated and efficacious.
Combination Therapy Development
The ELEVATE study explores elacestrant combinations with other targeted therapies, reflecting oncologists’ preference for doublet regimens to achieve superior disease control. Multiple study arms investigate combinations with different CDK4/6 inhibitors and PI3K/mTOR pathway inhibitors. Early results from ASCO 2025 show promising preliminary data for several combination approaches.
The combination of elacestrant with ribociclib demonstrated median progression-free survival slightly above 7 months, while the elacestrant plus everolimus combination achieved impressive results of 8 to 9 months. These combination approaches appear well-tolerated without new safety signals beyond known individual drug profiles. The maintained safety profile supports the feasibility of these combination strategies.
These combination studies represent the next frontier in ESR1-targeted therapy, potentially offering enhanced efficacy over single-agent approaches. The encouraging preliminary data suggests that elacestrant can serve as an effective backbone for combination regimens, potentially extending treatment duration and improving outcomes for patients with ESR1-mutated breast cancer.
Related Content:
